Expanded Data on Disability and Cognitive Improvements in Phase II Study of Synthetic Biologics’ Trimesta™ in Multiple Sclerosis to be Presented at 2014 Joint ACTRIMS-ECTRIMS Meeting
July 31, 2014
— Oral Presentation to Include Greater Detail on Clinical Outcomes, Including Significant and Unique Improvements in Cognition —
ROCKVILLE, Md., July 31, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (nyse mkt:SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that Rhonda Voskuhl, M.D., the lead investigator of the Phase II clinical trial evaluating Trimesta™, the Company’s oral product candidate for the treatment of relapsing-remitting multiple sclerosis (MS), is scheduled to present additional clinical outcome data, including more detailed results on cognitive and disability measures. The data will be presented at the 2014 Joint Americas and European Committees for Treatment and Research in Multiple Sclerosis Meeting (ACTRIMS-ECTRIMS) in Boston.
The abstract titled, A Combination Trial of Estriol Plus Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis: Effects on Disabilities, will be featured in an oral presentation on Friday, September 12, 2014, at 8:39am (ET).
“We are thrilled that Dr. Voskuhl will present additional clinical findings for Trimesta, an oral agent for treating MS in women. The presentation provides further data on the Phase II topline efficacy results reported in April 2014, comparing Trimesta in combination with Copaxone® to Copaxone® alone as an active control arm. The presentation is expected to provide details about the significant clinical outcome measures including relapse rate, disability, and cognition measures evaluated in this compelling trial,” stated Jeffrey Riley, Chief Executive Officer of Synthetic Biologics. “If the findings are supported in further studies, Trimesta, either alone or in combination with other MS drugs, could become a leading front-line therapy for women with MS due to its unique and differentiated anti-inflammatory, as well as neuroprotective benefits.”
Dr. Voskuhl commented, “The clinically significant improvement in cognitive testing in women taking Trimesta in this Phase II study is of high importance for MS specialists and patients. We believe the differentiated mechanism of action observed with Trimesta presents a new oral opportunity and has the potential to be an ideal added oral therapy to address significant unmet needs for women affected by this progressive, debilitating condition.”
